The supercritical water oxidation (SCWO) system is a secondary waste processing reactor of the Blue Grass Chemical Agent Destruction Pilot Plant (BGCAPP). It is perhaps second in importance behind the agent neutralization reactors, which perform base hydrolysis of chemical warfare agents stored at the Blue Grass Army Depot.

An international commission has been convened by the U.S. National Academy of Medicine, the U.S. National Academy of Sciences, and the Royal Society of the U.K., with the participation of science and medical academies around the world, to develop a framework for scientists, clinicians, and regulatory authorities to consider when assessing potential clinical applications of human germline genome editing.

For some patients, the ability to participate in a clinical trial from the comfort of one’s home is becoming a reality.

The U.S. National Academies recognize the significance of the opioid crisis and have been at the forefront of efforts to advise our nation on how to combat it.

The International Commission on the Clinical Use of Human Germline Genome Editing is tasked with identifying the scientific, medical, and ethical requirements to consider when assessing potential clinical applications of human germline genome editing — if society concludes that heritable human genome editing applications are acceptable.

The federal government should foster collaboration and decrease obstacles that can keep foreign atomic, molecular, and optical (AMO) physicists from working in the United States, if the nation is to maintain its position as leader in these fields, says a new report from the National Academies of Sciences, Engineering, and Medicine.

For severe acute pain due to surgeries and medical conditions, there is a lack of guidance on the appropriate type, strength, and amount of opioid medication that clinicians should prescribe to patients, says a new report from the National Academies of Sciences, Engineering, and Medicine.

As a novel coronavirus spreads throughout the world and the number of cases and deaths continues to rise, almost no country or community remains untouched by this rapidly evolving threat.

Over the next five years, the U.S. Department of Defense’s Biological Threat Reduction Program (BTRP) should encourage and be among co-leaders in the federal government’s development of an enduring interagency mechanism to address an array of biological threats – including natural disease outbreaks, accidental releases, and intentional attacks -- to deployed U.S. forces and to the nation itself, says a new report from the National Academies of Sciences, Engineering, and Medicine

The U.S. Department of Energy’s plan to dilute and dispose of 34 metric tons of surplus plutonium in the Waste Isolation Pilot Plant (WIPP) in New Mexico is technically viable, provided that the plan’s implementation challenges and system vulnerabilities are resolved.

Perk Labs has formally launched new verticals and unveiled the...

President Trump speaks at the White House Friday. He is replacing an official who issued a report that found testing delays and equipment shortages at hospitals.; Credit: Jim Watson/AFP via Getty Images

President Trump is moving to replace the Department of Health and Human Services watchdog whose office found severe shortages of medical supplies in hospitals as COVID-19 cases surged.

In a Friday night announcement, the White House named Jason Weida as its nominee to take the permanent inspector general post currently occupied by Christi Grimm, who's been in that role in an acting capacity since January.

A longtime staffer with Health and Human Services, Grimm was leading the inspector general's office in April when it issued a report chronicling testing delays — up to seven days in some cases — as well as severe shortages of supplies in hospitals amid the COVID-19 pandemic.

"Hospitals reported that they were unable to keep up with COVID-19 testing demands because they lacked complete kits and/or the individual components and supplies needed to complete tests," the survey of 323 hospitals found. "When patient stays were extended while awaiting test results, this strained bed availability, personal protective equipment (PPE) supplies, and staffing."

The report also recalled how one hospital had even resorted to making its own disinfectant.

Trump reacted to the report by calling its findings "wrong," asking to know the name of the inspector general and suggesting the report was politically motivated. He later took to Twitter to castigate Grimm and the report even further.

"Why didn't the I.G., who spent 8 years with the Obama Administration (Did she Report on the failed H1N1 Swine Flu debacle where 17,000 people died?), want to talk to the Admirals, Generals, V.P. & others in charge, before doing her report. Another Fake Dossier!" Trump tweeted in early April.

Grimm is a career official, not a political appointee, and began serving in the Office of the Inspector General in 1999.

The nomination of Weida — currently an assistant U.S. attorney — marks the latest replacement of a high-level watchdog by the president. A month ago, he fired the inspector general who raised concerns that eventually led to his impeachment. Days later, he removed the inspector general charged with overseeing the government's coronavirus response bill.

Sen. Patty Murray, ranking Democrat on the Health, Education, Labor and Pensions Committee, said that Trump's nominee "must not get through the Senate without ironclad commitments" to continue the agency's current investigations without political interference.

"We all know the President hasn't told people the truth about this virus or his Administration's response, and late last night, he moved to silence an independent government official who did," Murray said in a statement released on Saturday. "Anyone who demands less will be complicit in the President's clear pattern of retaliation against those who tell the truth."

Health and Human Services did not comment to NPR on Grimm's future role, but said in statement that the agency had been preparing "to assist a new Inspector General appointee over a year ago, when the previous presidentially-appointed and senate-confirmed Inspector General first announced his intention to retire from government service. We will continue to work conscientiously to support a smooth leadership transition."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Senate Majority Leader Mitch McConnell has made filling judicial vacancies his top priority ahead of the 2020 elections.; Credit: J. Scott Applewhite/AP

As new allegations emerge about his motives for retirement, Judge Thomas Griffith says that he faced no political pressure in his decision to leave the bench.

"My decision was driven entirely by personal concerns and involved no discussions with the White House or the Senate," he said in a statement provided to NPR.

Griffith said that his wife was diagnosed 11 years ago with a "debilitating chronic illness" and that her health was "the sole reason for my retirement." He said he made the decision to retire in June 2019 and privately informed his family and law clerks at the time. His retirement was announced publicly in March.

Griffith, 65, is a circuit court judge on the U.S. Court of Appeals for the District of Columbia. Appointed by President George W. Bush, he has served since 2005.

On Monday, The New York Times reported that Demand Justice, a liberal judicial advocacy group, filed a complaint that raises questions about whether Griffith's decision was tied to efforts by Senate Majority Leader Mitch McConnell to encourage older, conservative judges to retire in order to fill their vacancies with younger, conservative judges ahead of the 2020 election, when control of the White House and the Senate will be in play.

Griffith's retirement has paved the way for Justin Walker's nomination to fill the vacancy. Walker, 37, is a longtime McConnell ally who is currently serving as a U.S. district judge of the Western District of Kentucky, McConnell's home state.

The Demand Justice complaint was directed to the U.S. Court of Appeals, where the court's chief judge, Sri Srinivasan, has asked Chief Justice John Roberts to assign another circuit to look into the complaint about whether any ethical improprieties occurred. Griffith's statement refutes the core allegation — that his decision was fueled by political considerations or the result of a pressure campaign.

These allegations are likely to come up at Walker's confirmation hearing on Wednesday before the Senate Judiciary Committee.

Democrats broadly oppose Walker's nomination. He was rated "not qualified" by the American Bar Association. However, unless support for him is diminished among Republicans — unlikely with McConnell's backing — he is likely to be confirmed.

This content is from Southern California Public Radio. View the original story at SCPR.org.

A 2018 exhibit at the Billy Ireland Cartoon Library & Museum at Ohio State University celebrated the artistic legacy of MAD magazine.; Credit: Andrew Welsh-Huggins/AP

The funny, freckled face of Alfred E. Neuman is more or less retiring.

One of the last widely circulated print satirical magazines in America will leave newsstands after this year, according to sources at DC Comics, which publishes MAD magazine.

While the Harvard Lampoon remains in business, The Onion hasn't been in print since 2013. The once-influential Spy was a casualty of the 1990s.

At MAD's peak in the early 1970s, more than 2 million people subscribed to it, both for its pungent political humor and deeply adolescent jokes.

In 2017, that number had reportedly dropped to 140,000.

MAD isn't completely shutting down, but it will be radically downsized and changed.

Readers will only be able to find the 67-year-old humor magazine at comic book stores and through subscriptions.

After issue No. 10 this fall, there will no longer be new content, except for end-of-year specials which will be all new. Starting with issue No. 11, the magazine will feature classic, best-of and nostalgic content, repackaged with new covers.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Emily Quinn speaks from the TED stage at TEDWomen 2018; Credit: /TED

Part 1 of the TED Radio Hour episode The Biology Of Sex

Artist Emily Quinn is intersex. She's one of over 150 million people in the world who don't fit neatly into the categories of male or female. She explains how biological sex exists on a spectrum.

About Emily Quinn

Emily Quinn is an artist and activist. She worked at Cartoon Network on the Emmy Award winning show, Adventure Time. While there she partnered with interACT and MTV to develop the first intersex main character in television history. She came out publicly as intersex in a PSA alongside the character's debut. She later worked as the Youth Coordinator for interACT: Advocates for Intersex Youth.

As an activist, she speaks about intersex issues before audiences and through her YouTube channel: intersexperiences. As an artist, her most recent projects include a genderless puberty guidebook and a portrait series of intersex people that will be exhibited at medical schools across the U.S. in 2020.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Commercial sea fishing has been taking place for centuries. The first analysis of historic data from the UK has indicated that, over the past 118 years, the commercial productivity of UK fisheries has decreased by 94 per cent.

Image modeling for biomedical organs

Emily Quinn speaks from the TED stage at TEDWomen 2018; Credit: /TED

Part 1 of the TED Radio Hour episode The Biology Of Sex

Artist Emily Quinn is intersex. She's one of over 150 million people in the world who don't fit neatly into the categories of male or female. She explains how biological sex exists on a spectrum.

About Emily Quinn

Emily Quinn is an artist and activist. She worked at Cartoon Network on the Emmy Award winning show, Adventure Time. While there she partnered with interACT and MTV to develop the first intersex main character in television history. She came out publicly as intersex in a PSA alongside the character's debut. She later worked as the Youth Coordinator for interACT: Advocates for Intersex Youth.

As an activist, she speaks about intersex issues before audiences and through her YouTube channel: intersexperiences. As an artist, her most recent projects include a genderless puberty guidebook and a portrait series of intersex people that will be exhibited at medical schools across the U.S. in 2020.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Shares of ION Geophysical traded higher after the company reported Q1/20 financial results that included a 53% year-over-year increase in revenue.

By ranking the ???hazard potential??? of a wide range of chemicals used to make common plastics, Swedish researchers have highlighted which plastic polymers are made from the most hazardous chemicals. These should be prioritised for assessing the risk of causing human or environmental harm.

To date, it has been difficult to collect data that are robust enough to demonstrate specific effects of chemical pollution in rivers on aquatic wildlife. However, a recent study combining detailed chemical, toxicological and ecological data in three European river basins now provides evidence linking cause and effect by revealing significant differences in the effects of differently polluted sediments on the organisms living in the river basins and the riverbed biodiversity.

Researchers in Berlin have demonstrated that urban wasteland areas can be used as suitable habitats for a range of grassland species. Using simple and cost-effective measures to sow grassland seed mixtures, they found that such areas flourished despite poor soil conditions and high levels of impact from people.

A recent study compared the decentralised treatment of pharmaceutical contaminants in wastewater at hospitals with centralised treatment at conventional and upgraded wastewater plants. The results suggest that additional (post) treatments may not always provide significant benefits.

A recent study has revealed how water use has changed across the world over the last 60 years. Growing populations and economic development, particularly in newly-emerging countries, have increased water demand, but technological developments have led to water efficiencies and savings, which moderate these demands.

In 1989, researchers dragged a plough harrow across the seafloor of the Peru Basin to recreate some of the effects of deep-sea mining. Twenty-six years later, a new team of researchers returned to the site to assess whether there were any long-term ecological effects. They found that the seabed ecosystem remained disrupted, with significantly fewer suspension feeder species, such as anemones and sea sponges, than in undisturbed areas of seafloor. This suggests that deep-sea mining could cause irreversible changes to marine food webs in highly disturbed areas.

New research has recommended using both ecological and carbon footprints to assess the impact of environmental policies and strategies at a regional level. The combination can provide an evidence-based means of evaluating policies to help achieve environmental targets.

Researchers in Berlin have demonstrated that urban wasteland areas can be used as suitable habitats for a range of grassland species. Using simple and cost-effective measures to sow grassland seed mixtures, they found that such areas flourished despite poor soil conditions and high levels of impact from people.

University of Oregon researchers have found links between the levels of antimicrobial chemicals and antibiotic-resistance genes in the dust of an aging building used for athletics and academics.

read more

Using archival documents, a new report published online by JAMA Internal Medicine examines the sugar industry's role in coronary heart disease research and suggests the industry sponsored research to influence the scientific debate to cast doubt on the hazards of sugar and to promote dietary fat as the culprit in heart disease.

read more

In the aftermath of natural disasters, displaced communities require temporary accommodation. A new study has examined how the built environment of these temporary communities influences their recovery and resilience, using accommodation set up after Hurricane Katrina as a case study. It highlights the importance of developing transitional built environments that consider the social and mental health needs of a community.

Producing and consuming food has a significant environmental impact. In the search for a sustainable diet, researchers in Sweden explored a method of food production that does not exceed the level of globally available arable land per capita, and involves raising livestock on pasture or by-products not suitable for humans (the ‘ecological leftovers’ principle). The researchers developed three diets based on this method and evaluated their environmental impact compared with current diets.

Outside the laboratory, living organisms are never subject to single stressors at set doses. In the real world, they face an intricate array of physical, chemical and biological environmental stressors that vary in space and time. The problem of assessing these complex risks for human health and the environment is a great challenge for scientists and regulators alike. For example, even if Maximum Permissible Concentrations (MPCs) for individual contaminants are not exceeded in water, in combination they can still be potentially hazardous to wildlife. This thematic issue reports on scientific research which can help us overcome some of the challenges associated with assessing the combination effects of chemicals.

New research in Spain has explored solutions to reducing traffic noise, and suggests that the best option is to combine global measures, such as speed restrictions, and local measures, such as noise screens.

People living close to road, rail and aircraft noise are likely to experience negative health effects. Long-term noise exposure may lead to problems with their heart and circulatory (cardiovascular) system and night-time noise is particularly disruptive of sleep patterns, which in turn may lead to cardiovascular health problems, a review of research into the effects of noise on cardiovascular diseases has found.

The lifetime environmental impacts of non-electrical consumer products, such as clothes, could be cut by over 40% if consumers maintained them in a more environmentally friendly manner, new research suggests. The study found the impacts of eco-designed products fell significantly when user guidelines were included in the eco-design.

A recent study has analysed risks to European renewable industries from the Chinese supply of critical raw materials. The offshore wind sector was found to be the most vulnerable of the renewable industries to supply risks. EU and industry strategies should be able to deal with these supply risks in the short term, but there are potential long-term risks to solar and wind sectors. The development of alternative technologies less reliant on these raw materials, and methods to recycle these materials is, therefore, a priority.

Adapting to climate change in coastal cities needs further development of the resilience approach as well as identifying how it can be practically used in local actions, according to a new study. The researchers present resilience as a flexible, practical way of dealing with climate change's impacts, such as coastal flooding, which can be easily built into adaptation measures.

Land cleared in the tropics loses nearly twice as much carbon and produces less than half the annual crop yield as land in temperate zones, according to researchers. Their analysis of the trade-off between crop production and the loss of carbon stored in vegetation highlights the need to target reforestation in the tropics.

A new report on biofuels by the UK’s Nuffield Council on Bioethics has produced a set of five ethical principles to guide the development of biofuels technology and policy. It recommends applying these principles to create comprehensive standards to ensure that biofuels address, rather than exacerbate, global problems.

A recent study has projected changes in the spread of malaria caused by climate change and climate variability in Africa by including the effect of variations in land use on local climate. It concludes that the risk of malaria epidemics is likely to shift from the north to the south of the Sahel, and to highland areas previously free of the disease.

US researchers have found that promoting the environmental benefits of energy-efficient products may actually deter some people from buying them. Since environmental issues have become politically polarised, those who hold more conservative views are less likely to purchase products that are marketed using environmental benefits, they argue.

A measure of ‘chemical footprint’ is being developed by researchers to assess the environmental impacts of the toxic chemicals released by the production and consumption of goods. The methodology, based on life cycle and risk assessment, is also designed to be linked to the resilience of ecosystems to chemical exposure.

Mining metals from landfill sites can be economically viable, a recent project in the US has demonstrated. Approximately 34 352 tonnes of metals, conservatively valued at US$7.42 million (€6.67 million) were recovered from the 8 hectare ashfill site, according to researchers who analysed the project.

A participatory approach to waste management has been tested in Naples, Italy, a city which has experienced ongoing problems with the collection of municipal waste. This study tested a toolkit, which uses stakeholder engagement to improve waste-management decision-making. Residents and other stakeholders supported the use of a technological innovation to develop biomass fuel from municipal waste.

Food packaging waste is currently under scrutiny. In the context of its Circular Economy Action Plan, the EU is addressing this through, among others, its Product Environmental Footprint (PEF) initiative , which aims to enhance the reliability of environmental claims — both in a business-to-consumer and in a business-to-business context. The initiative aims, therefore, to boost the market of green and circular products. However, a review of the methods available for assessing the environmental sustainability of packaging now highlights the difficulty of clearly characterising packaging's environmental impact. The study suggests a new, fully quantifiable framework that could help to standardise assessment methods and bring 'environmental footprint labelling' to fruition.